Study Tests New Medication for Chronic Coronary Heart Disease
A new drug to reduce inflammation shows no added benefit in patients with stable heart disease.
Inflammation has been linked to heart disease in many large studies. Lp-PLA2, a marker of inflammation measured in the bloodstream, is blocked by a new medication called darapladib. However, according to a study presented at the American College of Cardiology’s 63rd Scientific Session, darapladib failed to show a survival benefit in patients who were already treated with optimal medications for their heart disease.
This study, known as STABILITY, enrolled 15,828 patients with stable heart disease in different countries. Half of them received the oral medication darapladib. The medication was generally well tolerated without major safety concerns during the 3.7 year follow-up period. Darapladib showed no significant benefit in reducing first heart attacks, stroke, or death from heart disease. The most common side effect of this medication was diarrhea, which led to stopping the drug among some participants.
Future studies are underway to see if patients that are suffering from heart attacks may receive additional benefits from treatment with darapladib.